Literature DB >> 29272330

Anthracycline cardiotoxicity: the importance of horizontally integrating pre-clinical and clinical research.

Steven E Lipshultz1, Eugene H Herman2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29272330      PMCID： PMC5852510          DOI： 10.1093/cvr/cvx246

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN： 0008-6363            Impact factor:   10.787


× No keyword cloud information.
  50 in total

1.  Examination of the potential long-lasting protective effect of ICRF-187 against anthracycline-induced chronic cardiomyopathy.

Authors:  E H Herman; V J Ferrans
Journal:  Cancer Treat Rev       Date:  1990-09       Impact factor: 12.111

2.  Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics.

Authors:  Kristopher A Sarosiek; Cameron Fraser; Nathiya Muthalagu; Patrick D Bhola; Weiting Chang; Samuel K McBrayer; Adam Cantlon; Sudeshna Fisch; Gail Golomb-Mello; Jeremy A Ryan; Jing Deng; Brian Jian; Chris Corbett; Marti Goldenberg; Joseph R Madsen; Ronglih Liao; Dominic Walsh; John Sedivy; Daniel J Murphy; Daniel Ruben Carrasco; Shenandoah Robinson; Javid Moslehi; Anthony Letai
Journal:  Cancer Cell       Date:  2016-12-22       Impact factor: 31.743

3.  Spironolactone ameliorates the cardiovascular toxicity induced by concomitant trastuzumab and thoracic radiotherapy.

Authors:  Guler Yavas; Esin Celik; Cagdas Yavas; Cagdas Elsurer; Rengin Elsurer Afsar
Journal:  Rep Pract Oncol Radiother       Date:  2017-05-05

4.  Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer.

Authors:  Steven E Lipshultz; Stuart R Lipsitz; Stephen E Sallan; Valeriano C Simbre; Seema L Shaikh; Suzanne M Mone; Richard D Gelber; Steven D Colan
Journal:  J Clin Oncol       Date:  2002-12-01       Impact factor: 44.544

5.  Inhibition of the cardiac myocyte mineralocorticoid receptor ameliorates doxorubicin-induced cardiotoxicity.

Authors:  Achim Lother; Stella Bergemann; Jessica Kowalski; Michael Huck; Ralf Gilsbach; Christoph Bode; Lutz Hein
Journal:  Cardiovasc Res       Date:  2018-02-01       Impact factor: 10.787

6.  The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.

Authors:  Steven E Lipshultz; Nader Rifai; Virginia M Dalton; Donna E Levy; Lewis B Silverman; Stuart R Lipsitz; Steven D Colan; Barbara L Asselin; Ronald D Barr; Luis A Clavell; Craig A Hurwitz; Albert Moghrabi; Yvan Samson; Marshall A Schorin; Richard D Gelber; Stephen E Sallan
Journal:  N Engl J Med       Date:  2004-07-08       Impact factor: 91.245

7.  Cardiac matrix alterations induced by adriamycin.

Authors:  J B Caulfield; V Bittner
Journal:  Am J Pathol       Date:  1988-11       Impact factor: 4.307

8.  Monitoring for anthracycline cardiotoxicity.

Authors:  S E Lipshultz; S P Sanders; A M Goorin; J P Krischer; S E Sallan; S D Colan
Journal:  Pediatrics       Date:  1994-03       Impact factor: 7.124

9.  Cardiac troponin-I, brain natriuretic peptide and endothelin-1 levels in a rat model of doxorubicin-induced cardiac injury.

Authors:  Erman Atas; Erol Kismet; Vural Kesik; Baki Karaoglu; Gokhan Aydemir; Nadir Korkmazer; Erkan Demirkaya; Yıldirim Karslioglu; Neval Yurttutan; Bulent Unay; Vedat Koseoglu; Erdal Gokcay
Journal:  J Cancer Res Ther       Date:  2015 Oct-Dec       Impact factor: 1.805

Review 10.  Dexrazoxane for the treatment of chemotherapy-related side effects.

Authors:  Seppo W Langer
Journal:  Cancer Manag Res       Date:  2014-09-15       Impact factor: 3.989
View more
  12 in total

Review 1.  Cardiovascular diseases in survivors of childhood cancer.

Authors:  Neha Bansal; Javier G Blanco; Umesh C Sharma; Saraswati Pokharel; Shannon Shisler; Steven E Lipshultz
Journal:  Cancer Metastasis Rev       Date:  2020-03       Impact factor: 9.264

2.  Biolayer interferometry provides a robust method for detecting DNA binding small molecules in microbial extracts.

Authors:  Ross D Overacker; Birte Plitzko; Sandra Loesgen
Journal:  Anal Bioanal Chem       Date:  2020-11-25       Impact factor: 4.142

3.  Letter by Lipshultz Regarding Article, "Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?"

Authors:  Steven E Lipshultz
Journal:  Circ Res       Date:  2018-03-30       Impact factor: 17.367

Review 4.  Molecular mechanisms of doxorubicin-induced cardiotoxicity: novel roles of sirtuin 1-mediated signaling pathways.

Authors:  Jie Wang A; Jingjing Zhang; Mengjie Xiao; Shudong Wang; Jie Wang B; Yuanfang Guo; Yufeng Tang; Junlian Gu
Journal:  Cell Mol Life Sci       Date:  2021-01-13       Impact factor: 9.261

Review 5.  Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity.

Authors:  Becky Meiners; Chetan Shenoy; Beshay N Zordoky
Journal:  Biol Sex Differ       Date:  2018-08-29       Impact factor: 5.027

6.  Advantages of prophylactic versus conventionally scheduled heart failure therapy in an experimental model of doxorubicin-induced cardiomyopathy.

Authors:  Mária Lódi; Dániel Priksz; Gábor Áron Fülöp; Beáta Bódi; Alexandra Gyöngyösi; Lilla Nagy; Árpád Kovács; Attila Béla Kertész; Judit Kocsis; István Édes; Zoltán Csanádi; István Czuriga; Zoltán Kisvárday; Béla Juhász; István Lekli; Péter Bai; Attila Tóth; Zoltán Papp; Dániel Czuriga
Journal:  J Transl Med       Date:  2019-07-19       Impact factor: 5.531

7.  Prophylactic, single-drug cardioprotection in a comparative, experimental study of doxorubicin-induced cardiomyopathy.

Authors:  Mária Lódi; Viktor Bánhegyi; Beáta Bódi; Alexandra Gyöngyösi; Árpád Kovács; Anita Árokszállási; Nazha Hamdani; Miklós Fagyas; István Édes; Zoltán Csanádi; István Czuriga; Zoltán Kisvárday; István Lekli; Péter Bai; Attila Tóth; Zoltán Papp; Dániel Czuriga
Journal:  J Transl Med       Date:  2020-12-09       Impact factor: 5.531

8.  Electrochemical, spectroscopic and theoretical monitoring of anthracyclines' interactions with DNA and ascorbic acid by adopting two routes: Cancer cell line studies.

Authors:  Fouzia Perveen; Nasima Arshad; Rumana Qureshi; Jahanzaib Nowsherwan; Aiesha Sultan; Bushra Nosheen; Hummera Rafique
Journal:  PLoS One       Date:  2018-10-29       Impact factor: 3.240

Review 9.  Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors.

Authors:  Neha Bansal; M Jacob Adams; Sarju Ganatra; Steven D Colan; Sanjeev Aggarwal; Rudolf Steiner; Shahnawaz Amdani; Emma R Lipshultz; Steven E Lipshultz
Journal:  Cardiooncology       Date:  2019-12-02

Review 10.  Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors?

Authors:  Syril D Pettit; Rebecca Kirch
Journal:  Cardiooncology       Date:  2018-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.